The other principal investigators are:
• Tomasz Beer, MD, Oregon Health & Science University
• Martin Gleave, MD, University of British Columbia
• Hsing-Jien Kung, PhD, University of California, Davis
• Joshua Stuart, PhD, University of California, Santa Cruz
And advocates on the team are:
• Arthur Kern, UCSF
• Roy Doumani, UCLA
The Dream Team will help identify the causes of resistance in individual prostate cancer patients and help tailor therapy for each patient, according to a news release issued by the American Association for Cancer Research, SU2C’s scientific partner.
It is organized around five working groups integrating expertise from each of the six centers, with a sixth “knowledge-exchange” working group coordinating Dream Team activities addressing therapeutic interventions for advanced prostate cancer with special emphasis on metastatic disease and delivering near-term patient benefit.
The team will explore the idea that resistance is a result of prostate cancer cells using adaptive pathways to escape current therapies, with the theory that by identifying and inhibiting these pathways it would be possible to overcome treatment resistance and extend survival and improve quality of life.
MedBook--a social network for medical science application similar to an iPad app--is also being developed by Ted Goldstein, a former Apple VP. This precision prostate oncology application will link patients, doctors, and researchers to help speed the matching of new therapies “targeted at nine new druggable pathways to the patients who will benefit most,” according to the release.
Kathleen Lobb, a SU2C cofounder and EIF senior vice president, told me that Stand Up has a mantra about being nimble in order to take advantage of great research opportunities.
“The SU2C and PCF representatives on the Joint Scientific Advisory Committee, as well as AACR, were enthusiastic about two of the finalist prostate cancer Dream Team proposals,” she said. “We announced the first team, and then both organizations decided to made additional financial commitments, so with that and funding from other donors, we were delighted to name a second prostate cancer team.”
The new team will begin work later this fall, with the first clinical trials scheduled to open in 2013, and is expected to collaborate with the first Prostate Cancer Dream Team, “Precision Therapy for Advanced Prostate Cancer,” announced in April at AACR’s annual meeting.
Team one is also a joint project of SU2C and PCF, and is led by Arul M. Chinnaiyan, MD, PhD, of the University of Michigan, and Charles L. Sawyers, MD, of Memorial Sloan-Kettering Cancer Center. The goal of that team is to decode the cancer genomes of 500 treatment-resistant prostate cancer patients to help direct them to the most effective therapies.